A physiologically based pharmacokinetic model for [⁶⁸Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients.

ABSTRACT:

Background

Little is known about parameters that have a relevant impact on (dis)similarities in biodistribution between various ⁶⁸Ga-labeled somatostatin analogues. Additionally, the effect of tumor burden on organ uptake remains unclear. Therefore, the aim of this study was to describe and compare organ and tumor distribution of [⁶⁸Ga]Ga-DOTATATE and [⁶⁸Ga]Ga-HA-DOTATATE using a physiologically based pharmacokinetic (PBPK) model and to identify factors that might cause biodistribution and tumor uptake differences between both peptides. In addition, the effect of tumor burden on peptide biodistribution in gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients was assessed.

Methods

A PBPK model was developed for [⁶⁸Ga]Ga-(

SUBMITTER: Siebinga H 

PROVIDER: S-EPMC9898489 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature